Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 1997

View Archived Issues

Pharmacia & Upjohn describes HIV reverse transcriptase inhibitors

Japanese scientists report cholecystokinin antagonists

Potent antitumor agents described by Daiichi

Antifungal agent described by Roussel Morishita

New MDR modulators disclosed by Vertex

New antimigraine agent from Pfizer

PDE IV inhibitors revealed by Byk Gulden

New COX-2 inhibitor series reported by Merck Frosst

New PDE IV/TNF inhibitors from Chiroscience

Searle describes antiinflammatory oxazoles

Xoma expands pivotal Neuprex trials

Boston Life Sciences accelerates development of Altropane

AEterna accelerates anticancer clinical program

FDA proposes withdrawal of terfenadine products

Third set of phase III trials on Diatide imaging agent commences

Combination protease inhibitor trial with 141W94/VX-478

FDA clears antimetastatic carbohydrate compound for human trials

Aronex out-licenses antibody-toxin complex

Inhale/Centeon agreement for alpha1-proteinase inhibitor

SyStemix to be integrated into Novartis

Gene Logic/Baylor prostate cancer collaboration

Stanford researchers isolate breast cancer gene

Roche/Genentech marketing agreement for Roferon-A

3DP and ViroPharma establish drug discovery collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...